|
CA3108071A1
|
|
Anti-cxcr2 antibodies and uses thereof
|
|
WO2019126614A1
|
|
Antibody peptide mapping and characterization using an erlic-ms/ms method
|
|
US2019062421A1
|
|
Treatment strategy for non-responders to 100mg subcutaneous mepolizumab
|
|
KR20200019630A
|
|
Cation Exchange Chromatography Wash Buffer
|
|
KR20190097094A
|
|
Antibodies Specific to Human IL-15 and Uses thereof
|
|
MX2019007642A
|
|
Anti-il-5 antibodies.
|
|
US2018056018A1
|
|
Inhalation Systems, Devices and Methods
|
|
US2018021696A1
|
|
Affinity chromatography wash buffer
|
|
EP3484519A1
|
|
Pharmaceutical prodrugs and methods of their preparation and use
|
|
TW201722990A
|
|
Antibodies that specifically bind to tl1a
|
|
US2018327351A1
|
|
Prodrugs of chlorokynurenines
|
|
PE20180572A1
|
|
1,4-SUBSTITUTED PIPERIDINE DERIVATIVES
|
|
EP3237408A1
|
|
Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
|
|
AU2015275266A1
|
|
Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
|
|
AU2015353549A1
|
|
Crystalline forms of PARP inhibitors
|
|
WO2016044369A1
|
|
Nanoparticulate and macroparticulate formulations
|
|
HUE050202T2
|
|
Use of reslizumab to treat moderate to severe eosinophilic asthma
|
|
US2016303116A1
|
|
Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
|
|
WO2015038868A1
|
|
Fused bicyclic 2,4-diaminopyrimidine derivatives
|
|
TW201536291A
|
|
Methods of treating various cancers using an AXL/cMET inhibitor alone or in combination with other agents
|
